Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COX-2 Gastrointestinal Safety Profile Questioned By BMJ Study

This article was originally published in The Pink Sheet Daily

Executive Summary

British Medical Journal researchers were concerned to find increased risk for rofecoxib since lower GI risk “was one of the main justifications for use.”

You may also be interested in...

Celebrex, Mobic Not Worth Extra Expense, Journal Analysis Finds

Payors and consumers overspent nearly $6 bil. over three years by choosing celecoxib and meloxicam over traditional, less-expensive therapies, according to Journal of Managed Care Pharmacy.

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts